Obesity drugs face price pressure
The weight‑loss drug market is moving from scarcity toward price competition as low‑cost semaglutide copies in India are already cutting into incumbents’ shares. Eli Lilly responded by launching an oral obesity pill, Foundayo, priced from $149 a month, while logistics for Novo’s Wegovy eased with an EU shipping rule allowing up to 30°C for 48 hours — and senior personnel moves at Novo were also reported. (bloomberg.com) (benzinga.com) (stocktwits.com) (endpoints.news)
A drug that used to be hard to find is starting to look more like toothpaste on a crowded shelf. In India, cheap copies of semaglutide are already cutting into Eli Lilly’s early obesity-drug lead just weeks after Novo Nordisk’s key semaglutide patent expired there on March 20. (bloomberg.com) Semaglutide is the ingredient behind Novo Nordisk’s Ozempic and Wegovy, and India is one of the first big markets where the patent wall has come down. Bloomberg reported that about 42 drugmakers are expected to launch products under more than 50 brand names this year. (bloomberg.com) That matters because Lilly had moved fast in India with Mounjaro, its rival obesity and diabetes shot, while Novo was still protected by patents in many richer markets. India is now giving investors a live preview of what happens when semaglutide stops being a premium, protected product and starts competing on price. (bloomberg.com) Lilly’s answer this month was not to cut the price of its injection first. It launched Foundayo, the brand name for orforglipron, a once-daily obesity pill that Lilly says can be taken any time of day without food or water restrictions. (medical.lilly.com) Lilly is also using price as a weapon. On its Foundayo savings pages, Lilly says self-pay patients can get a one-month supply starting at $149 for the 0.8 milligram dose, with higher doses starting at $199, $249, $349, $499, and $549 a month. (foundayo.lilly.com) That is a different pitch from the first wave of obesity drugs, when the story was mostly shortages, waiting lists, and insurance fights. An oral pill with a posted cash price turns the market into something closer to a menu, where convenience and monthly cost can matter as much as brand prestige. (foundayo.lilly.com) Novo Nordisk got a different kind of help on April 9. The company said Wegovy became the first glucagon-like peptide 1 weight-loss treatment approved in the European Union for 48-hour controlled-temperature delivery, allowing shipping at up to 30 degrees Celsius. (novonordisk.com) That sounds like a small packaging change, but these drugs are temperature-sensitive injections, so shipping rules can decide which pharmacies can stock them and how far they can travel without expensive cold-chain handling. A 48-hour window at up to 30 degrees Celsius makes distribution easier in the same way a package that no longer needs ice packs gets cheaper to move. (novonordisk.com) Novo is also dealing with people changes while the market gets tougher. Endpoints reported that glucagon-like peptide 1 pioneer Lotte Bjerre Knudsen is retiring, and Novo is also losing an obesity leader to Boehringer Ingelheim. (endpoints.news) Put those pieces together and the obesity-drug business looks less like a gold rush and more like an airline fare war. India is showing what patent expiry does to prices, Lilly is pushing a cheaper pill into the United States market, and Novo is trying to make its flagship injection easier to ship and defend. (bloomberg.com)
